VIFNZ Stock Overview
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vifor Pharma AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF166.00 |
| 52 Week High | CHF197.10 |
| 52 Week Low | CHF157.75 |
| Beta | 1.04 |
| 1 Month Change | -2.09% |
| 3 Month Change | -6.87% |
| 1 Year Change | 1.84% |
| 3 Year Change | n/a |
| 5 Year Change | 32.91% |
| Change since IPO | 62.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| VIFNZ | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.3% | 1.7% | 1.0% |
| 1Y | 1.8% | 5.2% | 3.0% |
Return vs Industry: VIFNZ exceeded the UK Pharmaceuticals industry which returned -7.1% over the past year.
Return vs Market: VIFNZ exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| VIFNZ volatility | |
|---|---|
| VIFNZ Average Weekly Movement | 2.2% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VIFNZ has not had significant price volatility in the past 3 months.
Volatility Over Time: VIFNZ's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1872 | 2,200 | n/a | www.viforpharma.com |
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD) It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis.
Vifor Pharma AG Fundamentals Summary
| VIFNZ fundamental statistics | |
|---|---|
| Market cap | CHF10.78b |
| Earnings (TTM) | CHF146.60m |
| Revenue (TTM) | CHF1.81b |
73.1x
P/E Ratio5.9x
P/S RatioIs VIFNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIFNZ income statement (TTM) | |
|---|---|
| Revenue | CHF1.81b |
| Cost of Revenue | CHF671.80m |
| Gross Profit | CHF1.14b |
| Other Expenses | CHF993.70m |
| Earnings | CHF146.60m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.26 |
| Gross Margin | 62.93% |
| Net Profit Margin | 8.09% |
| Debt/Equity Ratio | 13.6% |
How did VIFNZ perform over the long term?
See historical performance and comparison